Ms. Samira Sakhia reports

NOTICE OF KNIGHT THERAPEUTICS' FOURTH QUARTER AND YEAR END 2025 RESULTS CONFERENCE CALL

Knight Therapeutics Inc. will release its fourth quarter and year-end 2025 financial results on Thursday, March 19, 2026, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date:  Thursday, March 19, 2026

Time:  8:30 a.m. ET

Telephone:  toll-free at 1-888-699-1199 or international at 1-416-945-7677

Webcast:  A listen-only audio webcast will be available on the company's website. Media Player is required to listen to the broadcast.

Replay:  An archived replay will be available for 30 days on the company's website.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.